Patent protected
Indian Patent No. 202511025669 with an active WIPO PCT filing.
Sequoia Insilico Pvt. Ltd. · BioAI for brain & mental health
Connected intelligence for brain and mental healthcare.
SIPL connects clinical care, behavioural signals, neuroscience, genomics, and discovery in one responsible AI infrastructure. LifeBack™ is our flagship clinical platform for multimodal, clinician-supported mental-health assessment and longitudinal care.
GrantedIndian patent
97%HAM-D agreement
500+hospital assessments
BIRACgrant-backed validation
SIPL · FLAGSHIP PLATFORM: LIFEBACK™
Voice
Video
Clinical
Genomics
ONE
STRUCTURED
VIEW
STRUCTURED
VIEW
Evidence-linked contextconfidence · uncertainty · longitudinal change
The proof, up front
Validated. Protected. Built in India. Ready for the world.
Validated in hospital
97% agreement with the HAM-D clinical standard across 500+ assessments.
Grant-backed
A BIRAC GCE-III grant deployed into product development and validation.
India-native
Engineered with interoperability and the Indian health stack in mind.
The SIPL intelligence architecture
Care, hospital, and discovery, connected in one system.
SIPL is building infrastructure that connects point-of-care assessment, hospital workflows, and governed scientific discovery. LifeBack™ is the clinical doorway into this larger ecosystem.
CARE INTELLIGENCE
Care intelligence
Multimodal assessment, risk and severity scoring, longitudinal monitoring, and structured decision support built around the clinician.
Explore capabilityHOSPITAL INTELLIGENCE
Hospital intelligence
Connected patient context, structured psychiatric workflows, and interoperable records designed for modern health systems.
Explore capabilityDISCOVERY INTELLIGENCE
Discovery intelligence
A governed research layer for biomarkers, patient stratification, multimodal studies, and real-world evidence.
Explore capabilityA SYSTEM THAT LEARNS
Every stage strengthens the next.
01UnderstandBring permitted information into one context.
02AssessIdentify clinically relevant patterns across signals.
03PersonaliseBuild an individualised view of risk and response.
04DeliverConnect insight to professional workflow.
05MonitorTrack meaningful change and outcomes over time.
06DiscoverReturn governed evidence to the next study.
LifeBack™ · SIPL flagship clinical platform
One evidence-linked view of depression, built from audio, video, and clinical signals.
LifeBack™ brings audio, video, and a structured clinical interview into a single assessment workflow. It organises and measures the signals; the clinician interprets the full picture and makes the care decision.
LifeBack™Professional assessment workspace
CLINICIAN-SUPPORTEDASSESSMENT FLOW
One patient. Multiple signals. One integrated assessment.
The modalities are considered together so no single audio, video, or questionnaire signal is treated as the diagnosis.
Audio assessment
Speech and voice features are analysed as behavioural clinical context.
Signal qualityClinical context
Video assessment
Facial and behavioural signals provide complementary information.
Signal qualityClinical context
Clinical interview & scales
A structured interview flow is combined with standardised measures.
Signal qualityClinical context
MULTIMODAL FUSIONEvidence-linked assessment contextconfidence · uncertainty · agreement
LIFEBACK™ / CLINICIAN VIEWASSESSMENT
Structured outputProfessional reviewReview all modalities together
AI
Professional interpretation required. LifeBack™ supports assessment and decision-making; it does not replace clinical evaluation.
GrantedIndian patent
97%HAM-D agreement
500+hospital assessments
Science & evidence
Research is not a phase. It is the foundation.
Every model, biomarker, and clinical pathway is treated as a testable scientific hypothesis that must earn its place in care.
97%
agreement with HAM-D across 500+ assessments at RML Hospital.
Research starts with clinical relevance and a defined intended use.
Evidence is examined across complementary biological, behavioural, and clinical signals.
Performance, uncertainty, limitations, and subgroup behaviour are evaluated explicitly.
Qualified professionals remain responsible for interpretation and care.
Literature grounding→Ethics review→Data quality→Model evaluation→External validation
Who we serve
One ecosystem. A distinct pathway for every partner.
Hospitals & health systems
Structured pathways, connected workflows, longitudinal monitoring, and outcome intelligence.
Clinicians
Clear, longitudinal, and explainable information that supports professional interpretation.
Researchers
Governed multimodal studies, biomarker investigation, and clinical evidence generation.
Biopharma
Patient stratification, clinical-development support, and real-world evidence built around the research question.
Genomics partners
Connect genomic information to clinically relevant longitudinal context.
Public health & investors
Responsible population programmes and a platform thesis connecting care with discovery.
BioAI for biopharma
Connect patient biology, clinical outcomes, and therapeutic discovery.
SIPL's multimodal intelligence infrastructure supports responsible research across discovery, clinical development, and real-world evidence.
Discuss a research objectiveBiomarker researchdisease · progression · response · safety
Patient stratificationclinically and biologically meaningful cohorts
Clinical-study intelligencecharacterisation · outcome measurement · follow-up
Pharmacogenomic researchtreatment response · tolerability · variability
Real-world evidencegoverned longitudinal data beyond controlled trials
About SIPL
Building enduring intelligence for better brain health.
Sequoia Insilico Pvt. Ltd. is a deep-science BioAI company working at the intersection of clinical care, artificial intelligence, neuroscience, genomics, and life-sciences research.
Since its 2019 pivot from computational-biology services, SIPL has focused on making brain and mental health measurable, longitudinal, and precise.
Meet the teamTurn fragmented information into useful, explainable intelligence.
Treat every model and pathway as open to testing and revision.
Keep clinical safety, privacy, and human oversight at the centre.
Communicate evidence, uncertainty, and limitations with discipline.
Investors & strategic partners
A specialised BioAI platform connecting care and discovery.
SIPL is building intelligence infrastructure at the convergence of brain health, multimodal biomarkers, genomics, clinical workflows, and biopharma research.
Domain depth
Specialised focus on brain and mental health.
Multimodal context
Clinical, behavioural, biological, and longitudinal information in one record.
Ecosystem reach
Applications across care, research, genomics, and biopharma.
Responsible scale
Human oversight, validation, and transparent limitations built in.
WHY NOW, WHY SIPL
Validated, protected, India-native, and globally relevant.
97% HAM-D agreement500+ assessmentsFHIR R4 directionSeed round active
Request investor accessResponsible AI, security & trust
AI supports the professional. The professional leads the care.
Define why information is used and the permissions that apply.
Limit access to authorised responsibilities.
Apply appropriate safeguards to sensitive information.
Maintain traceable actions, versions, and review pathways.
Keep qualified professionals accountable for interpretation and care.
Define intended use, validation, monitoring, and change control.
Security and compliance
Privacy, role-based access, auditability, and human oversight are designed into the platform architecture.
The vision
From one intelligence layer to a population-scale brain-health atlas.
SIPL is building toward an AI-native model of care where multimodal assessment, genomic and imaging data, EHR context, decision support, and longitudinal monitoring converge into one discovery-linked system.
Partner with SIPL
Let's build the next generation of brain and mental healthcare.
Hospital, research, genomics, biopharma, or investment: start with the objective and we will route the conversation to the right team.
Start a conversation New Delhi, India